To include your compound in the COVID-19 Resource Center, submit it here.
GENZ and partner DCRN said preliminary analysis of a U.S. Phase II trial in 18 patients with severe PD showed NeuroCell-PD did not meet its
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury